Pancreatic Cancer Research

ResearcherKagoshima UniversityActive in the last 2 years

Tetsuya Idichi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8048-2203; OpenAlex author ID A5016601963. Sources: OpenAlex.

Their work

Papers
19 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
48
Papers, trials and grants by year

2017: 3 papers · 2018: 2 papers · 2019: 2 papers · 2020: 3 papers · 2021: 3 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 19

  1. International multicenter validation of an 18F-fluorodeoxyglucose positron emission tomography/computed tomography maximum standardized uptake value 4.0 thresh… Co-author DOI 10.1016/j.surg.2026.110503↗
  2. Aldehyde Dehydrogenase 2 Activity Assessed Using the Acetaldehyde Breath Test Is Associated with Benign Pancreatic Disease and Pancreatic Cancer: A Case-Contro… Co-author DOI 10.3390/jcm15197543↗
  3. Strategies to Target the Tumor-Associated Macrophages in the Immunosuppressive Microenvironment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers17183090↗
  4. Genetic Assessment of Intraductal Papillary Mucinous Neoplasm for Predicting Concomitant Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002373↗
  5. Coronin 1C, Regulated by Multiple microRNAs, Facilitates Cancer Cell Aggressiveness in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/genes14050995↗
  6. Implications of PD-1, Tim-3, and TIGIT Expression for Cancer Immunity and Pancreatic Cancer Prognosis. Co-author DOI 10.21873/anticanres.15824↗
  7. Effectiveness of Adjuvant Therapy in Patients with Pancreatic Cancer Who Underwent Neoadjuvant Therapy. Co-author DOI 10.1245/s10434-021-09712-6↗
  8. Impact of Oncogenic Targets Controlled by Tumor-Suppressive miR-30a-5p in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.15297↗
  9. Clinical Benefits of Conversion Surgery for Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Institution, Retrospective Analysis. Co-author DOI 10.3390/cancers13051057↗
  10. Lung recurrence and its therapeutic strategy in patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.11.015↗
  11. Molecular Pathogenesis of Pancreatic Ductal Adenocarcinoma: Impact of miR-30c-5p and miR-30c-2-3p Regulation on Oncogenic Genes. Co-author DOI 10.3390/cancers12102731↗
  12. Role of miR-30a-3p Regulation of Oncogenic Targets in Pancreatic Ductal Adenocarcinoma Pathogenesis. Co-author DOI 10.3390/ijms21186459↗
  13. Gene regulation by antitumor miR-130b-5p in pancreatic ductal adenocarcinoma: the clinical significance of oncogenic EPS8. Co-author DOI 10.1038/s10038-019-0584-6↗
  14. Gene Regulation by Antitumor miR-204-5p in Pancreatic Ductal Adenocarcinoma: The Clinical Significance of Direct RACGAP1 Regulation. First author DOI 10.3390/cancers11030327↗
  15. Molecular pathogenesis of pancreatic ductal adenocarcinoma: Impact of passenger strand of pre-miR-148a on gene regulation. Co-author DOI 10.1111/cas.13610↗
  16. Involvement of anti-tumor miR-124-3p and its targets in the pathogenesis of pancreatic ductal adenocarcinoma: direct regulation of ITGA3 and ITGB1 by miR-124-3… Co-author DOI 10.18632/oncotarget.25599↗
  17. ZFP36L2 promotes cancer cell aggressiveness and is regulated by antitumor microRNA-375 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cas.13119↗
  18. Regulation of actin-binding protein ANLN by antitumor miR-217 inhibits cancer cell aggressiveness in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.18261↗
  19. The microRNA expression signature of pancreatic ductal adenocarcinoma by RNA sequencing: anti-tumour functions of the microRNA-216 cluster. Co-author DOI 10.18632/oncotarget.19591↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiroshi Kurahara · 16 shared papers, 2017–2024 · strength 1.70
  2. Yuko Mataki · 13 shared papers, 2017–2026 · strength 1.62
  3. Takao Ohtsuka · 10 shared papers, 2020–2026 · strength 1.62
  4. Yuto Hozaka · 7 shared papers, 2020–2025 · strength 1.06
  5. Naohiko Seki · 11 shared papers, 2017–2023 · strength 1.02
  6. Kosei Maemura · 9 shared papers, 2017–2021 · strength 0.72
  7. Shoji Natsugoe · 8 shared papers, 2017–2020 · strength 0.60
  8. Chieri Nakayama · 2 shared papers, 2022–2025 · strength 0.41
  9. Kosuke Fukuda · 2 shared papers, 2023–2024 · strength 0.37
  10. Takako Tanaka · 3 shared papers, 2020–2021 · strength 0.34
  11. Haruhi Fukuhisa · 4 shared papers, 2018–2019 · strength 0.31
  12. Michiyo Higashi · 2 shared papers, 2020–2024 · strength 0.29
  13. Ryu Matsumoto · 1 shared paper, 2025 · strength 0.27
  14. Shiho Arima · 1 shared paper, 2026 · strength 0.24
  15. Shinichi Hashimoto · 1 shared paper, 2026 · strength 0.24
  16. Makoto Hinokuchi · 1 shared paper, 2026 · strength 0.24
  17. Yusuke Kamikihara · 1 shared paper, 2026 · strength 0.24
  18. Hiroki Shimomura · 2 shared papers, 2020–2022 · strength 0.24
  19. Isamu Makino · 1 shared paper, 2026 · strength 0.19
  20. Atsushi Tomioka · 1 shared paper, 2026 · strength 0.19
  21. Teiichi Sugiura · 1 shared paper, 2026 · strength 0.19
  22. Shintaro Yagi · 1 shared paper, 2026 · strength 0.19
  23. Yoo‐Seok Yoon · 1 shared paper, 2026 · strength 0.19
  24. Kousei Ishigami · 1 shared paper, 2026 · strength 0.19
  25. Hongbeom Kim · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.